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Lowering homocysteine in patients with ischemic stroke to prevent
recurrent stroke, myocardial infarction, and death: The vitamin inter-
vention for stroke prevention (VISP) randomized controlled trial
Toole JF, Malinow MR, Chambless LE, et al. JAMA 2004; 291:565-75.
Conclusion: Vitamin therapy resulting in moderate reductions of total
homocysteine after a nondisabling cerebral event has no affect on vascular
outcomes during a 2-year follow up period.
Summary: The authors sought to determine if high doses of folic acid,
pyridoxine (vitamin B6), and cobamalin (vitamin B12) could lower the risk of
death, recurrent cerebral infarction, and coronary heart disease in patients
with a nondisabling cerebral infarction. A total of 3680 adults with nondis-
abling cerebral infarction were randomized at 56 centers to receive best
medical and surgical care plus a daily vitamin containing either high-dose
formulations of pyridoxine (25 mg), cobamalin (0.4 mg), and folic acid (2.5
mg) or a low-dose formulations containing 200 g of pyridoxine, 6 g of
cobamalin, and 20 g of folic acid.
There was a graded and persistent association between baseline total
homocysteine level and outcome. Risk association with baseline homocys-
teine level was numerically slightly lower in the high-dose group for all
events but was not statistically different from that in the low-dose group.
Mean total homocysteine levels were reduced to a greater extent in the
high-dose group than in the low-dose group (2 mol/L). There were no
differences in the high-dose or low-dose groups with respect to recurrent
cerebral infarction, coronary heart disease, or death. There was an 18%
chance of an event within 2 years in the high-dose vitamin group and an
18.6% chance of an event within 2 years in the low-dose vitamin group. The
risk of ischemic stroke within 2 years was 9.2% for the high-dose and 8.8% for
the low-dose group (P  .80).
Comment: The lack of treatment effect of vitamin therapy on cardio-
vascular end points observed in this study may be due to several factors.
Homocysteine levels in the study population were relatively low and treat-
ment effects may be more pronounced in patients with higher levels of
homocysteine. Alternatively, US government–mandated folic acid supple-
mentation of the grain supply may have mitigated additional vitamin effects.
A longer period of observation may also be necessary to observe treatment
effect.
Endovascular treatment of isolated atherosclerotic stenosis of the in-
frarenal abdominal aorta: Long-term outcome
Feugier P, Toursarkissian B, Chevalier J-M, et al. Ann Vasc Surg 2003;17:
375-85.
Conclusion: Aortic angioplasty is an effective treatment for isolated
atherosclerotic stenosis of the infrarenal abdominal aorta, with primary
patency rates of 94% at 1 year, 89% at 3 years, and 77% at 5 years.
Summary: A total of 86 patients (36 women, 50 men, mean age
53.2 12.7 years) from 18 European centers who underwent endovascular
treatment of symptomatic atherosclerotic occlusive lesions of the infrarenal
abdominal aorta were evaluated. Only cases of isolated stenosis confined to
the infrarenal aorta 10 mm from the aortic bifurcation were included.
Indication for treatment was claudication in 74 of the 86 cases. Mean
preprocedure ankle-brachial index was 0.71 and mean diameter reduction of
the aorta was 77%. There was circumferential aortic calcification in 35%. A
single balloon technique was used in 60 cases and a double balloon tech-
nique in 26 cases. Stents were employed in 88% of cases.
There was one mortality unrelated to treatment of the aortic lesion.
There were four technical failures with residual stenosis 30%. Early mor-
bidity occurred in 9.3% and included retroperitoneal hematoma in one
patient, peripheral embolism in two patients, and puncture site hematoma in
three patients. Survival at 3 years was 91%. Primary patency of the angio-
plasty sight was 94% at 1 year, 89% at 3 years, and 77% at 5 years. Three
patients developed aortic thrombosis at the treatment site at 8, 41, and 49
months, respectively. Sixty-five patients (76%) were symptomless at last
follow-up. The mean ankle-brachial index at follow-up was 0.89 (P  .01
compared with pretreatment values). Age, gender, length of stenosis, cir-
cumferential aortic calcification, and stent usage did not affect long-term
patency.
Comment: This article has all of the disadvantages of a retrospective
study, including varying techniques of angioplasty, different stents, lack of
consistent use of pressure gradients, and no consistent follow-up protocol.
Nevertheless, very acceptable initial technical success and reasonable long-
term primary patency appear possible with aortic dilatation.
P2Y12 H2 haplotype is associated with peripheral arterial disease: A
case controlled study
Fontana P, Gaussen P, Haiach M, et al. Circulation 2003;108:2971-2973.
Conclusion: The H2 haplotype of the platelet ADP receptor P2Y12
may be important in the development of atherosclerotic peripheral arterial
disease (PAD) independent of diabetes, smoking, hypertension, and hyper-
cholesterolemia.
Summary: After platelet adhesion to endothelium, platelet aggrega-
tion participates in development of atherosclerosis through release of growth
factors and cytokines. The P2Y12 receptor for ADP is particularly important
in mediating platelet aggregation in patients with PAD. Specific blockage of
this receptor by clopidogrel provides benefit against ischemic events in
patients with PAD compared with those with histories of myocardial infarc-
tion and stroke with no known PAD (Lancet 1996:348;1329-1339). There
are two haplotypes of the P2Y12, H1 and H2, with H2 leading to greater
ADP-induced platelet aggregation. The authors tested the link between the
H2 haplotype of P2Y12 and PAD in a case controlled study.
Male patients 70 years of age with PAD (n  184) were compared
with 330 age-matched controls free of symptomatic PAD. In univariant
analysis the H2 haplotype was more frequent in patients with PAD than in
control subjects (30% and 21%, respectively; odds ratio 1.6; confidence
interval 1.1-2.5; P .02). In multivariable analysis this association remained
significant after adjustment for diabetes, smoking, hypertension, hypercho-
lesterolemia, and other platelet receptor gene polymorphisms (odds ratio
2.3; confidence interval 1.4-3.9; P  .002).
Comment: The data indicate a possible role for a specific gene poly-
morphism in the development of PAD. Genetic testing may some day be
employed to determine which antiplatelet agent is likely to have the greatest
protective effect in an individual patient with PAD.
Mechanism of ischemic infarct in spontaneous carotid dissection
Benninger DH, Georgiadias D, Kremer C, et al. Stroke 2004;35:482-5.
Conclusion: Thromboembolism, not hemodynamic infarction, is the
primary stroke mechanism in patients with spontaneous carotid dissection.
Summary: The authors retrospectively evaluated brain computed to-
mography (CT) and magnetic resonance (MR) scans and ultrasound find-
ings of 141 consecutive patients with 143 spontaneous carotid dissections
causing ischemic stroke. Eleven patients were excluded because of technical
considerations or treatment with thrombolysis. Overall, data from 130
patients with 131 spontaneous carotid dissections were analyzed.
There were 76 men and 54 women in the study, mean age 45  11
years. Carotid artery dissections were unilateral in 123 cases (94%). Three
patients had asymptomatic dissection of the opposite internal carotid artery,
and three patients had asymptomatic dissection of a vertebral artery. Isch-
emic strokes were studied by MR imaging and CT in 72% of patients, MR
imaging alone in 8% of patients, and CT alone in 20% of patients. Territorial
infarcts, indicative of thromboembolic disease, were found in all patients.
Additional border zone infarcts, indicating hemodynamic infarction, were
seen in six patients. Territorial infarcts affected the middle cerebral artery in
130 of the 131 cases. Patterns of cross flow, degree of internal carotid artery
stenosis, number of middle cerebral and anterior cerebral artery occlusions,
and middle cerebral artery stenoses did not differ between carotid artery
dissections causing territorial and border zone infarcts and those dissections
only resulting in territorial infarcts. Recurrent ischemic events were observed
in three patients during the first 2 weeks. All were transient ischemic attacks.
Comment: The overwhelming mechanism for ischemic infarct in pa-
tients with spontaneous carotid dissection is thromboembolism. A throm-
boembolic mechanism of ischemic infarction in spontaneous carotid dissec-
tion likely explains the well-recognized therapeutic benefit of
anticoagulation for treatment of spontaneous carotid dissection.
Peripheral arterial disease in people with diabetes: American Diabetes
Association Consensus Statement
Diabetes Care 2003; 26:3333-41.
Summary/Conclusions: This article grew out of a consensus confer-
ence held May 7-8, 2003, under the hospices of the American Diabetes
Association. Four topics were addressed: (1) the epidemiology and impact of
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